Cara Therapeutics to Announce Second Quarter 2021 Financial Results on August 9, 2021
Cara Therapeutics (Nasdaq: CARA) will host a conference call on August 9, 2021, at 4:30 p.m. ET to discuss its second quarter 2021 financial results and provide a corporate update. The live audio webcast will be available on the company’s website, and an archived recording will be accessible shortly after the call. The company is focused on developing treatments for pruritus, particularly with its product KORSUVA, which has shown promise in clinical trials for patients with chronic kidney disease. The FDA has granted Priority Review for KORSUVA's NDA.
- KORSUVA Injection has demonstrated statistically significant reductions in itch intensity in clinical trials.
- FDA granted Priority Review for KORSUVA, with a PDUFA target action date of August 23, 2021.
- Oral KORSUVA has completed Phase 2 trials and is ongoing for several conditions.
- None.
STAMFORD, Conn., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Monday, August 9, 2021 at 4:30 p.m. ET to report second quarter 2021 financial results and provide a corporate update.
To participate in the conference call, please dial (855) 445-2816 (domestic) or (484) 756-4300 (international) and refer to conference ID 1568596. A live webcast of the call can be accessed under “Events & Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com.
An archived webcast recording will be available on the Cara website beginning approximately two hours after the call.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral KORs. Cara is developing a novel and proprietary class of product candidates, led by KORSUVA (CR845/difelikefalin), a first-in-class KOR agonist that targets KORs located in the peripheral nervous system and on immune cells. In the Company’s KALM™-1 and KALM-2 Phase 3 trials and two Phase 2 trials, KORSUVA Injection has demonstrated statistically significant reductions in itch intensity and concomitant improvement in pruritus-related quality of life measures in hemodialysis patients with moderate-to-severe CKD-aP. The FDA has accepted and granted Priority Review for the NDA for KORSUVA (difelikefalin) Injection for the treatment of moderate-to-severe pruritus in hemodialysis patients. The PDUFA target action date for KORSUVA is August 23, 2021. Oral KORSUVA has completed Phase 2 trials for the treatment of pruritus in patients with CKD and AD and is currently in Phase 2 trials in PBC and NP patients with moderate-to-severe pruritus.
The FDA has conditionally accepted KORSUVA as the trade name for difelikefalin injection. CR845/difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.
MEDIA CONTACT:
Claire LaCagnina
6 Degrees
315-765-1462
clacagnina@6degreespr.com
INVESTOR CONTACT:
Janhavi Mohite
Stern Investor Relations, Inc.
212-362-1200
janhavi.mohite@SternIR.com
FAQ
What are the key details of Cara Therapeutics' conference call on August 9, 2021?
What is the significance of KORSUVA for Cara Therapeutics?
When is the PDUFA target action date for KORSUVA?
